Benzinga’s News Roundup (NXY, PALM, TTEK, PERY, OSIP)
March 19, 2010 7:48 AM
Nexen Inc. (USA) (NYSE: NXY) and its partner reported today that they have made a significant discovery in the Eastern Gulf of Mexico at Appomattox, located in Mississippi Canyon blocks 391 and 392. Nexen increased 3.99% to $24.50 in the pre-market session. The 52-week trading range for NXY is $15.46 - $26.25. NXY closed at $23.56 in the last trading session.
Palm, Inc. (NASDAQ: PALM) was downgraded today by Kaufman Bros from Hold to Sell and the price target set to $3. Palm declined 18.23% to $4.63 in the pre-market session. The 52-week trading range for PALM is $5.29 - $18.09. Palm has declined over 59% in the last six months.
Tetra Tech, Inc. (NASDAQ: TTEK) was upgraded today by Janney Mntgmy Scott from Neutral to Buy. TTEK closed at $20.75 in the last trading session. The 52-week trading range for TTEK is $19.51 - $32.00. TTEK has declined over 24% in the last six months.
Perry Ellis International, Inc. (NASDAQ: PERY) announced that for fiscal 2011, it anticipates earnings per fully diluted share in the range of $1.25 - $1.40 and revenues to be in the range of $770 - $790 million, representing a low- to mid-single-digit increase. Analysts are expecting PERY to report EPS of $1.35 and revenue of $789 million for fiscal 2011. Perry Ellis International increased 1.44% to $23.30 in the pre-market session. Perry Ellis closed at $22.97 in the pre-market session. In the last six months, PERY has gained over 43%.
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that its international partner for Tarceva (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease following four cycles of standard platinum-based first-line chemotherapy. OSI Pharmaceuticals increased 0.51% to $59 in the pre-market session. The 52-week trading range for OSIP is $27.01 - $58.97. OSIP has gained over 67% in the last six months.
